Navigation Links
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage

World Alzheimer's Day 2008 Special Report: New innovative treatment approaches in Alzheimer's disease which involve mechanisms other than a direct attack on amyloid plaques have emerged as the leading candidates in the fight against Alzheimer's in 2008. These approaches were presented at ICAD 2008, the world's leading forum on dementia research. These new developments are discussed in the debut of, a new website which takes a critical look at the most important news in Alzheimer's research.

Los Angeles, CA (PRWEB) September 23, 2008 -- debuts with a World Alzheimer's Day 2008 Special Report, discussing the most significant developments which occurred in 2008 in the field of Alzheimer's disease research. The new report, available in both a video news report and in print at [], discusses several innovative therapeutics which address emerging new targets in Alzheimer's disease. These new therapeutics have taken center stage in 2008, after the prominent failure of the anti-amyloid investigational drugs tramiprosate(Alzhemed®, Neurochem) and Flurizan® (Myriad Genetics).

The promising new therapeutic agents discussed at ICAD 2008, the world's leading forum on dementia research, and in scientific publications in 2008, included the antihistamine Dimebon® (Medivation, now licensed to Pfizer); Rember®, a reforumulation of methylene blue (TauRX Therapeutics of Singapore); and a novel, off-label method of perispinal administration of etanercept. These agents are all hypothesized to address non-amyloid targets, including the tau tangles found in the brain(Rember®).

Among these agents etanercept is unique, because it was designed to correct an abnormality in the immune system, identified in Alzheimer's disease, which may affect brain function. This abnormality, an excess of the molecule TNF in the cerebrospinal fluid, is hypothesized to interfere with brain cell communication in patients with Alzheimer's disease and related forms of dementia. takes a critical look at the most important news in Alzheimer's research. The [ website] includes links to further reports and discussion regarding recent developments in Alzheimer's research. is sponsored by [the Institute for Neurological Research, a private medical group, inc. in Los Angeles], which has developed the perispinal etanercept anti-TNF strategy for dementia.

References: Doody, R.S., S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008. 372(9634): p. 207-15.

Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
2. New Lottery Ticket Envisions a World Free of MS
3. HTH Worldwide to Provide Mobile Healthcare Tool to HRG North Americas Affiliate Program
4. Kopernikus, observing our planet for a safer world
5. Substantial Second Quarter Surge for Angel MedFlight Worldwide Air Ambulance Services
6. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
9. IMRISneuro: The iMRI technology of choice among the worlds top ranked hospitals
10. Is Pleased to Announce That the Company Was Featured in the September 15th Issue of Womans World Magazine
11. UNC receives record $181 million grant to evaluate health, poverty and gender programs worldwide
Post Your Comments:
Related Image:
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
(Date:11/25/2015)... ... ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in Las ... Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers men ... surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use device ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) ... plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion of ... Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for his ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
(Date:11/25/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of ... Antonius Schuh, Ph.D., is scheduled to present a corporate ... Healthcare Conference. th Annual Piper Jaffray ... New York on Tuesday, December ... be available for one-on-one meetings during the conference. The ...
Breaking Medicine Technology: